← Leaderboards
Gabor Csanyi
University Of Pittsburgh At Pittsburgh
$4,521,951
Attributed
$4,521,951
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $563.7K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,521,951 · 4
By mechanism
R01$3,596,939 · 2
R00$747,000 · 1
K99$178,012 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Joanna Wysocka$10,388,791
- Johnny Huard$5,437,784
- J Peter Rubin$4,602,483
- Francisco Jose Schopfer$8,044,712
- Lisa Borghesi$5,860,621
Others in their field
Top investigators on “Attenuated”
- Lawrence Corey · Fred Hutchinson Cancer Center$124,686,255
- Stephen Lev Hoffman · Sanaria, Inc.$61,062,195
- Robert M. Grant · J. David Gladstone Institutes$48,731,024
- Jerri Edwards · University Of South Florida$42,327,407
- John C S Breitner · Johns Hopkins University$38,118,097
- Michael W Weiner · Northern California Institute Res &Educ$36,929,917
Research focus
AttenuatedSignal TransductionReceptorFoam CellsProteinsTherapeutic TargetIn VivoCellsIn VitroThrombospondin 1MediatingArterial Fatty StreakAntibodiesLipidsCd47 GeneAtherosclerosisAortaSmooth Muscle MyocytesPathway InteractionsPlayInflammatoryCostCardiovascular SystemApolipoprotein E
Grant awards (13)
SMC macropinocytosis: a novel target in atherosclerotic vascular disease$563,675
R01 · FY2025 · HL · contact PI
SMC macropinocytosis: a novel target in atherosclerotic vascular disease$552,402
R01 · FY2024 · HL · contact PI
SMC macropinocytosis: a novel target in atherosclerotic vascular disease$563,675
R01 · FY2023 · HL · contact PI
Lipid macropinocytosis: a novel target in atherosclerotic cardiovascular disease$385,000
R01 · FY2022 · HL · contact PI
Lipid macropinocytosis: a novel target in atherosclerotic cardiovascular disease$385,000
R01 · FY2021 · HL · contact PI
Lipid macropinocytosis: a novel target in atherosclerotic cardiovascular disease$384,687
R01 · FY2020 · HL · contact PI
Lipid macropinocytosis: a novel target in atherosclerotic cardiovascular disease$381,250
R01 · FY2019 · HL · contact PI
Lipid macropinocytosis: a novel target in atherosclerotic cardiovascular disease$381,250
R01 · FY2018 · HL · contact PI
A Novel Role of Macrophage TSP1-CD47 Signaling in Atherosclerosis$249,000
R00 · FY2017 · HL · contact PI
A Novel Role of Macrophage TSP1-CD47 Signaling in Atherosclerosis$249,000
R00 · FY2016 · HL · contact PI
A Novel Role of Macrophage TSP1-CD47 Signaling in Atherosclerosis$249,000
R00 · FY2015 · HL · contact PI
A Novel Role of Macrophage TSP1-CD47 Signaling in Atherosclerosis$88,012
K99 · FY2014 · HL · contact PI
A Novel Role of Macrophage TSP1-CD47 Signaling in Atherosclerosis$90,000
K99 · FY2013 · HL · contact PI